News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Nanotherapeutics Files Investigational New Drug Application for NanoDOX(TM) Hydrogel to Treat Lower Extremity Diabetic Ulcers


9/4/2008 8:40:43 AM

ALACHUA, Fla.--(BUSINESS WIRE)--Nanotherapeutics, a privately held specialty biopharmaceutical company, announced today that it has submitted its first Investigational New Drug (IND) application to the FDA for a phase IIa clinical study for its product NanoDOX™ Hydrogel, a topical doxycycline hydrogel for chronic wounds. The randomized double-blind study will assess the safety and efficacy of the product on the healing rates of non-infected diabetic ulcers of the lower extremity. Assuming FDA approval, the Company expects to complete enrollment in early 2009.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES